MHLA
Maiden Holdings, Ltd. 6.625 NT 2046
Insurance - Property & Casualty
Market Cap$1.24B
5Y Perf.-43.2%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
MHLA vs PRE vs EXAS vs ECCW
Revenue, margins, valuation, and 5-year total return — side by side.
PRE
Prenetics Global Limited
Medical - Diagnostics & Research
Market Cap$242M
5Y Perf.-85.9%
EXAS
Exact Sciences Corporation
Medical - Diagnostics & Research
Market Cap$20.02B
5Y Perf.-4.1%
ECCW
Eagle Point Credit Company Inc.
Asset Management
Market Cap$2.35B
5Y Perf.-4.8%
MHLA vs PRE vs EXAS vs ECCW — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MHLA | PRE | EXAS | ECCW |
|---|---|---|---|---|
| Industry | Insurance - Property & Casualty | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Asset Management |
| Market Cap | $1.24B | $242M | $20.02B | $2.35B |
| Revenue (TTM) | $42M | $69M | $3.25B | $116M |
| Net Income (TTM) | $-211M | $-47M | $-208M | $34M |
| Gross Margin | 100.0% | 47.2% | 69.7% | 84.2% |
| Operating Margin | 8.5% | -62.9% | -6.4% | 73.7% |
| Forward P/E | — | — | 582.8x | 29.3x |
| Total Debt | $255M | $2M | $2.52B | $272M |
| Cash & Equiv. | $35M | $32M | $956M | $42M |
MHLA vs PRE vs EXAS vs ECCW — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MHLA
PRE
EXAS
ECCW
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Maiden Holdings, Lt… (MHLA) | 100 | 56.8 | -43.2% |
| Prenetics Global Li… (PRE) | 100 | 14.1 | -85.9% |
| Exact Sciences Corp… (EXAS) | 100 | 95.9 | -4.1% |
| Eagle Point Credit … (ECCW) | 100 | 95.2 | -4.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MHLA vs PRE vs EXAS vs ECCW
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ECCW leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Prenetics Global Limited is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. EXAS also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
MHLA
Maiden Holdings, Ltd. 6.625 NT 2046
The Insurance Pick
MHLA is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta -0.05
Best for: income & stability
PRE
Prenetics Global Limited
The Growth Play
PRE is the #2 pick in this set and the best alternative if growth exposure and sleep-well-at-night is your priority.
- Rev growth 201.7%, EPS growth -14.0%, 3Y rev CAGR 91.5%
- Lower volatility, beta 0.27, Low D/E 1.3%, current ratio 3.01x
- 201.7% revenue growth vs MHLA's -36.8%
- +205.2% vs MHLA's -3.8%
Best for: growth exposure and sleep-well-at-night
EXAS
Exact Sciences Corporation
The Long-Run Compounder
EXAS is the clearest fit if your priority is long-term compounding and defensive.
- 16.7% 10Y total return vs ECCW's 37.0%
- Beta 0.12, current ratio 2.43x
- Beta 0.12 vs ECCW's 0.51
Best for: long-term compounding and defensive
ECCW
Eagle Point Credit Company Inc.
The Banking Pick
ECCW carries the broadest edge in this set and is the clearest fit for value and quality.
- Lower P/E (29.3x vs 582.8x)
- 69.3% margin vs MHLA's -5.1%
- 7.0% yield; the other 3 pay no meaningful dividend
- 2.2% ROA vs PRE's -23.7%, ROIC 6.1% vs -20.8%
Best for: value and quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRE | 201.7% revenue growth vs MHLA's -36.8% |
| Value | ECCW | Lower P/E (29.3x vs 582.8x) |
| Quality / Margins | ECCW | 69.3% margin vs MHLA's -5.1% |
| Stability / Safety | EXAS | Beta 0.12 vs ECCW's 0.51 |
| Dividends | ECCW | 7.0% yield; the other 3 pay no meaningful dividend |
| Momentum (1Y) | PRE | +205.2% vs MHLA's -3.8% |
| Efficiency (ROA) | ECCW | 2.2% ROA vs PRE's -23.7%, ROIC 6.1% vs -20.8% |
MHLA vs PRE vs EXAS vs ECCW — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2018
Segment breakdown not available.
FY 2025
Segment breakdown not available.
MHLA vs PRE vs EXAS vs ECCW — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLECCWLAGGINGPRE
Who Leads Where
ECCW leads in 2 of 6 categories
EXAS leads 1 • MHLA leads 0 • PRE leads 0 • 2 tied
Explore the data ↓PREPrenetics Global Limi…
0leads
MHLAMaiden Holdings, Ltd.…
0leads
EXASExact Sciences Corpor…
1leads
ECCWEagle Point Credit Co…
2leads
6 Total Categories
CATEGORYLEADERvs EXASvs MHLAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ECCW4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ECCW5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
EXAS3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ECCW leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
EXAS is the larger business by revenue, generating $3.2B annually — 78.1x MHLA's $42M. ECCW is the more profitable business, keeping 69.3% of every revenue dollar as net income compared to MHLA's -5.1%. On growth, PRE holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MHLAMaiden Holdings, … | PREPrenetics Global … | EXASExact Sciences Co… | ECCWEagle Point Credi… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $42M | $69M | $3.2B | $116M |
| EBITDAEarnings before interest/tax | -$4M | -$54M | -$41M | $63M |
| Net IncomeAfter-tax profit | -$211M | -$47M | -$208M | $34M |
| Free Cash FlowCash after capex | -$97M | $0 | $357M | $65M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +47.2% | +69.7% | +84.2% |
| Operating MarginEBIT ÷ Revenue | +8.5% | -62.9% | -6.4% | +73.7% |
| Net MarginNet income ÷ Revenue | -5.1% | -67.4% | -6.4% | +69.3% |
| FCF MarginFCF ÷ Revenue | -2.3% | -23.8% | +11.0% | +89.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -51.4% | +2.0% | +23.1% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -7.3% | +36.9% | +90.4% | +3.9% |
ECCW leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — PRE and ECCW each lead in 2 of 5 comparable metrics.
Valuation Metrics
On an enterprise value basis, ECCW's 30.2x EV/EBITDA is more attractive than MHLA's 69.4x.
| Metric | MHLAMaiden Holdings, … | PREPrenetics Global … | EXASExact Sciences Co… | ECCWEagle Point Credi… |
|---|---|---|---|---|
| Market CapShares × price | $1.2B | $242M | $20.0B | $2.4B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $212M | $21.6B | $2.6B |
| Trailing P/EPrice ÷ TTM EPS | -6.21x | -3.82x | -95.37x | 29.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 582.83x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 69.43x | — | — | 30.18x |
| Price / SalesMarket cap ÷ Revenue | 22.04x | 2.62x | 6.16x | 20.27x |
| Price / BookPrice ÷ Book value/share | 27.59x | 1.28x | 8.24x | 2.51x |
| Price / FCFMarket cap ÷ FCF | — | — | 56.10x | 22.70x |
Evenly matched — PRE and ECCW each lead in 2 of 5 comparable metrics.
Profitability & Efficiency
ECCW leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
ECCW delivers a 3.1% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-6 for MHLA. PRE carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to MHLA's 5.64x. On the Piotroski fundamental quality scale (0–9), EXAS scores 7/9 vs MHLA's 2/9, reflecting strong financial health.
| Metric | MHLAMaiden Holdings, … | PREPrenetics Global … | EXASExact Sciences Co… | ECCWEagle Point Credi… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -5.6% | -28.9% | -8.7% | +3.1% |
| ROA (TTM)Return on assets | -17.1% | -23.7% | -3.5% | +2.2% |
| ROICReturn on invested capital | +4.3% | -20.8% | -3.6% | +6.1% |
| ROCEReturn on capital employed | +1.5% | -21.2% | -4.0% | +7.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 5 | 7 | 3 |
| Debt / EquityFinancial leverage | 5.64x | 0.01x | 1.05x | 0.29x |
| Net DebtTotal debt minus cash | -$35M | -$30M | $1.6B | $230M |
| Cash & Equiv.Liquid assets | $35M | $32M | $956M | $42M |
| Total DebtShort + long-term debt | $255M | $2M | $2.5B | $272M |
| Interest CoverageEBIT ÷ Interest expense | -11.74x | -199.93x | -5.47x | 12.34x |
ECCW leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
EXAS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ECCW five years ago would be worth $13,385 today (with dividends reinvested), compared to $1,393 for PRE. Over the past 12 months, PRE leads with a +205.2% total return vs MHLA's -3.8%. The 3-year compound annual growth rate (CAGR) favors EXAS at 15.2% vs MHLA's 6.7% — a key indicator of consistent wealth creation.
| Metric | MHLAMaiden Holdings, … | PREPrenetics Global … | EXASExact Sciences Co… | ECCWEagle Point Credi… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -0.8% | +0.6% | +3.1% | +3.9% |
| 1-Year ReturnPast 12 months | -3.8% | +205.2% | +96.9% | +16.3% |
| 3-Year ReturnCumulative with dividends | +21.6% | +24.5% | +53.0% | +32.9% |
| 5-Year ReturnCumulative with dividends | -5.5% | -86.1% | +0.4% | +33.9% |
| 10-Year ReturnCumulative with dividends | +14.6% | -86.1% | +1669.1% | +37.0% |
| CAGR (3Y)Annualised 3-year return | +6.7% | +7.6% | +15.2% | +9.9% |
EXAS leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MHLA and EXAS each lead in 1 of 2 comparable metrics.
Risk & Volatility
MHLA is the less volatile stock with a -0.05 beta — it tends to amplify market swings less than ECCW's 0.51 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs PRE's 67.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MHLAMaiden Holdings, … | PREPrenetics Global … | EXASExact Sciences Co… | ECCWEagle Point Credi… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.05x | 0.27x | 0.12x | 0.51x |
| 52-Week HighHighest price in past year | $15.70 | $23.63 | $104.98 | $25.24 |
| 52-Week LowLowest price in past year | $9.93 | $5.07 | $38.81 | $6.74 |
| % of 52W HighCurrent price vs 52-week peak | +79.5% | +67.2% | +99.9% | +99.7% |
| RSI (14)Momentum oscillator 0–100 | 60.3 | 37.1 | 76.4 | 65.6 |
| Avg Volume (50D)Average daily shares traded | 3K | 186K | 4.2M | 3K |
Evenly matched — MHLA and EXAS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: PRE as "Buy", EXAS as "Buy". Consensus price targets imply 126.8% upside for PRE (target: $36) vs -1.6% for EXAS (target: $103). ECCW is the only dividend payer here at 6.97% yield — a key consideration for income-focused portfolios.
| Metric | MHLAMaiden Holdings, … | PREPrenetics Global … | EXASExact Sciences Co… | ECCWEagle Point Credi… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | — |
| Price TargetConsensus 12-month target | — | $36.00 | $103.18 | — |
| # AnalystsCovering analysts | — | 1 | 41 | — |
| Dividend YieldAnnual dividend ÷ price | — | — | — | +7.0% |
| Dividend StreakConsecutive years of raises | 0 | — | — | 0 |
| Dividend / ShareAnnual DPS | — | — | — | $1.75 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.3% | 0.0% | +0.1% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ECCW leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). EXAS leads in 1 (Total Returns). 2 tied.
Best OverallEagle Point Credit Company … (ECCW)Leads 2 of 6 categories
Loading custom metrics...
MHLA vs PRE vs EXAS vs ECCW: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is MHLA or PRE or EXAS or ECCW a better buy right now?
For growth investors, Prenetics Global Limited (PRE) is the stronger pick with 201.
7% revenue growth year-over-year, versus -36. 8% for Maiden Holdings, Ltd. 6. 625 NT 2046 (MHLA). Eagle Point Credit Company Inc. (ECCW) offers the better valuation at 29. 3x trailing P/E, making it the more compelling value choice. Analysts rate Prenetics Global Limited (PRE) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MHLA or PRE or EXAS or ECCW?
Over the past 5 years, Eagle Point Credit Company Inc.
(ECCW) delivered a total return of +33. 9%, compared to -86. 1% for Prenetics Global Limited (PRE). Over 10 years, the gap is even starker: EXAS returned +1669% versus PRE's -86. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MHLA or PRE or EXAS or ECCW?
By beta (market sensitivity over 5 years), Maiden Holdings, Ltd.
6. 625 NT 2046 (MHLA) is the lower-risk stock at -0. 05β versus Eagle Point Credit Company Inc. 's 0. 51β — meaning ECCW is approximately -1215% more volatile than MHLA relative to the S&P 500. On balance sheet safety, Prenetics Global Limited (PRE) carries a lower debt/equity ratio of 1% versus 6% for Maiden Holdings, Ltd. 6. 625 NT 2046 — giving it more financial flexibility in a downturn.
04Which is growing faster — MHLA or PRE or EXAS or ECCW?
By revenue growth (latest reported year), Prenetics Global Limited (PRE) is pulling ahead at 201.
7% versus -36. 8% for Maiden Holdings, Ltd. 6. 625 NT 2046 (MHLA). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -428. 9% for Maiden Holdings, Ltd. 6. 625 NT 2046. Over a 3-year CAGR, PRE leads at 91. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MHLA or PRE or EXAS or ECCW?
Eagle Point Credit Company Inc.
(ECCW) is the more profitable company, earning 69. 3% net margin versus -356. 1% for Maiden Holdings, Ltd. 6. 625 NT 2046 — meaning it keeps 69. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ECCW leads at 73. 7% versus -40. 5% for PRE. At the gross margin level — before operating expenses — MHLA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is MHLA or PRE or EXAS or ECCW more undervalued right now?
Analyst consensus price targets imply the most upside for PRE: 126.
8% to $36. 00.
07Which pays a better dividend — MHLA or PRE or EXAS or ECCW?
In this comparison, ECCW (7.
0% yield) pays a dividend. MHLA, PRE, EXAS do not pay a meaningful dividend and should not be held primarily for income.
08Is MHLA or PRE or EXAS or ECCW better for a retirement portfolio?
For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
12), +1669% 10Y return). Both have compounded well over 10 years (EXAS: +1669%, PRE: -86. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between MHLA and PRE and EXAS and ECCW?
These companies operate in different sectors (MHLA (Financial Services) and PRE (Healthcare) and EXAS (Healthcare) and ECCW (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: MHLA is a small-cap quality compounder stock; PRE is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock; ECCW is a small-cap income-oriented stock. ECCW pays a dividend while MHLA, PRE, EXAS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(MHLA: -51.4% · PRE: 202.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.